The Senate Judiciary Committee on Thursday (Nov. 21) voted 11-10 to pass an amended version of S. 2220, the Promoting and Respecting Economically Vital American Innovation Leadership (PREVAIL) Act, that aims to update mechanisms used by the Patent and Trademark Office’s Patent Trial and Appeal Board (PTAB) to adjudicate patent validity without preventing patient advocacy groups or generic drug makers from challenging patents, but further revisions to the bill are possible. Several lawmakers who voted for the bill argued the...